| Page | |
| EDITORIALS |
| 419 | Bronchial provocation testing: Should we look beyond FEV1?
|
| 421 | Is FeNOtyping in COPD the path to precision medicine?
|
| COMMENTARIES |
| 423 | Principles for consumer involvement in health and medical research
|
| 425 | FEV1 and pulmonary rehabilitation: Let's get the facts straight
|
| INVITED REVIEW |
| 428 | Contemporary Concise Review 2022: Chronic obstructive pulmonary disease
|
| ORIGINAL ARTICLES |
| Asthma and Allergy |
| 437 | Validation of the clinical utility of sGaw as a response variable in methacholine challenge testing
Jacqueline Parker, Allison Tzeng, Shawn Wayne, Jeffrey M Haynes, Charles G Irvin, David A Kaminsky
10.1111/resp.14431
Airway hyperresponsiveness may be reliably diagnosed by changes in specific airway conductance alone during methacholine challenge. Up to 34% of patients with clinically confirmed asthma would have been classified as having no airway hyperresponsiveness if only changes in FEV1 were used.
See related Editorial |
| COPD |
| 445 | Variability of fractional exhaled nitric oxide is associated with the risk and aetiology of COPD exacerbations
Desiree M Schumann, Eleni Papakonstantinou, Konstantinos Kostikas, Leticia Grize, Michael Tamm, Daiana Stolz
10.1111/resp.14439
Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) affect disease progression and are associated with considerable morbidity and mortality. Longitudinal measurements of FeNO revealed an association with future exacerbations. There is a differential increase of FeNO at exacerbations according to the aetiology and smoking status.
See related Editorial |
| Interstitial Lung Disease |
| 455 | MUC5B rs35705950 minor allele associates with older age and better survival in idiopathic pulmonary fibrosis
Joanne J van der Vis, Antje Prasse, Elisabetta A Renzoni, Carmel J W Stock, Canay Caliskan, Toby M Maher, Francesco Bonella, Raphael Borie, Bruno Crestani, Martin Petrek, Wim A Wuyts, Anne E Wind, Philip L Molyneaux, Jan C Grutters, Coline H M van Moorsel
10.1111/resp.14440
In idiopathic pulmonary fibrosis (IPF), the proportion of MUC5B rs35705950 minor allele carriers increases significantly with age. In IPF patients diagnosed at ≥56 years, transplant free survival is significantly better for MUC5B minor allele carriers compared to non-carriers. These findings support implementation of MUC5B genotyping for clinical prognostication in IPF. |
| 465 | Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial
Yoshikazu Inoue, Athol U Wells, Jin Woo Song, Zuojun Xu, Hideya Kitamura, Takafumi Suda, Masaki Okamoto, Heiko Müller, Carl Coeck, Klaus B Rohr, Martin Kolb, Kevin K Brown
10.1111/resp.14452
The INBUILD trial was a randomized placebo-controlled trial of nintedanib in patients with fibrosing ILDs that were progressing despite management in clinical practice. Data from the subgroup of Asian patients showed that nintedanib reduced the rate of decline in lung function with adverse events that were manageable for most patients. |
| Interventional Pulmonology and Lung Cancer |
| 475 |
Robotic bronchoscopic needle-based confocal laser endomicroscopy to diagnose peripheral lung nodules
Christopher J Manley, Tess Kramer, Rohit Kumar, Yulan Gong, Hormoz Ehya, Eric Ross, Peter I Bonta, Jouke T Annema
10.1111/resp.14438
Robotic bronchoscopic nCLE-imaging is feasible, safe and enables real-time visualization of tumour cells at the needle tip. Based on nCLE-guidance, the robotic bronchoscope was repositioned in almost half of patients. Our data show the potential of robotic bronchoscopic nCLE-imaging as a safe, improved strategy to diagnose small difficult-to-access lung nodules. |
| 484 | Dextromethorphan premedication in the alleviation of cough during flexible bronchoscopy in adults: A randomized double-blind placebo-controlled trial
Manoj Kumar Panigrahi, Ananda Datta, Sourin Bhuniya, Shakti Kumar Bal, Prasanta Raghab Mohapatra
10.1111/resp.14445
Cough is a usual phenomenon during flexible bronchoscopy and the ideal agent for cough suppression during flexible bronchoscopy is yet to be found. Dextromethorphan premedication administered orally 1 h before flexible bronchoscopy may have an additive effect on cough suppression over and above the conscious sedation and topical lignocaine. |
| FORUM AND DEBATE |
| Scientific Letter |
| 491 | Sputum periostin is a biomarker of type 2 inflammation but not airway dysfunction in asthma
Taha Al-Shaikhly, Ryan C Murphy, Ying Lai, Charles W Frevert, Jason S Debley, Steven F Ziegler, Kit Wong, Guiquan Jia, Cecile T J Holweg, Michael C Peters, Teal S Hallstrand
10.1111/resp.14491 |
| Personal Reflections |
| 495 | Urban living
|
| 496 | The big 5 respiratory diseases give insight into respiratory health and beyond
|
| 498 | Stirring the publishing pot by ending accept/reject decisions
|
| Letter from Asia-Pacific and Beyond |
| 500 | Letter from Norway
|
| CORRIGENDUM |
| 502 | Corrigendum
10.1111/resp.14497
This article corrects the following:
Abstracts
Volume 28 Issue S1 Respirology pages: 3-413 First Published online: 26 February 2023 |
